How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker
A world-renowned U.S. program for international disaster and crisis assistance can no longer deploy in the event of a major emergency due to the Trump administration's
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a
Health and humanitarian groups around the world were still uncertain on Wednesday if and how they could resume work after
The Trump administration's freeze on U.S. foreign aid globally has included a stop-work order to a program run by aid group Action Against Hunger helping severely
Field hospitals in Thai refugee camps, landmine clearance in war zones, and drugs to treat millions suffering from
Catalent Inc is close to reaching a settlement with Elliott Investment Management that would lead to a shake-up of the U.S. contract drug manufacturer’s board of directors after its share price lost half of its value in the last year. The company is poised to agree to add four new directors proposed by Elliott to its board, which currently has 12 members, people familiar with the situation said on Monday. The sources declined to be identified because the information is confidential and cautioned a deal could still collapse at the last minute. Spokespeople
Contract drug manufacturers seeking to tap into the booming market for weight-loss drugs are investing billions of dollars to expand or build factories that fill the
Novo Nordisk said on Thursday it will supply "significantly" more doses of Wegovy in the U.S. next year, even as it cautioned
Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their
John, a tech executive who has been battling weight gain since his 30s, has a nine-month supply in his refrigerator.
Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big
U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators,
Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already has strong sales of its
Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study
Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the
AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, boosted by demand for its blockbuster drugs and steady sales from
GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales
Novo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment, while
The main maternity hospital in the Gaza Strip's crowded southern city of Rafah has stopped admitting patients, the United Nations Population Fund (UNFPA) said on
AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the
Your subscription includes
Unlimited Access to All Content from
The Los Angeles Post
Your subscription has been successfully upgraded!